TABLE 2.

AST results of the Accelerate Pheno system compared to culture-based AST^a

Antimicrobial agent	Accelerate Pheno system AST							Culture-based AST (no.)
	No. of AST results	No. (%) of category agreements			No. (%) of minor discrepancies	No. (%) of major discrepancies	No. (%) of very major discrepancies	Susceptible	Resistant
		S	R/I	Total
SAM	66	31	32	63 (95.5)	0 (0)	3 (8.8)	0 (0)	34	32
TZP	91	78	6	84 (92.3)	0 (0)	7 (8.2)	0 (0)	85	6
FEP	90	73	6/1*	80 (88.9)	7 (7.8)	3 (3.6)	0 (0)	83	6/1*
CRO	85	75	8	83 (97.6)	0 (0)	2 (2.6)	0 (0)	77	8
ETP	85	85	0	85 (100)	0 (0)	0 (0)	0 (0)	85	0
MEM	94	91	2	93 (98.9)	1 (1.1)	0 (0)	0 (0)	91	3
AMK	95	91	2	93 (97.9)	1 (1.1)	0 (0)	1 (33.3)	92	3
GEN	94	84	9	93 (98.9)	0 (0)	1 (1.2)	0 (0)	85	9
TOB	94	82	10	92 (97.9)	1 (1.1)	1 (1.2)	0 (0)	84	10
CIP	94	69	21	90 (95.7)	4 (4.3)	0 (0)	0 (0)	73	21
CST	88	85	0	85 (96.6)	0 (0)	3 (3.4)	0 (0)	88	0
Total	976	844	97	941 (96.4)	14 (1.4)	20 (2.3)	1 (1.0)	876	100

^aThe overall category agreement was 96.4%. Minor discrepancies, major discrepancies, and very major discrepancies were detected in 1.4, 2.3, and 1.0%, respectively. *, One strain showed an intermediate result for FEP in the Accelerate Pheno system and culture-based ASTs. AMK, amikacin; SAM, ampicillin-sulbactam; FEP, cefepime; CRO, ceftriaxone; CIP, ciprofloxacin; GEN, gentamicin; MEM, meropenem; TZP, piperacillin-tazobactam; TOB, tobramycin; CST, colistin; ETP, ertapenem. S, susceptible; R/I, resistant/intermediate.